(Q43792927)

26 November 2017

Clevudine is highly efficacious in hepatitis B e antigen-negative chronic hepatitis B with durable off-therapy viral suppression (English)

1 reference

26 November 2017

1 reference

33

Sook-Hyang Jeong

1 reference

26 November 2017

16

Mong Cho

1 reference

26 November 2017

Byung Chul Yoo

1

1 reference

26 November 2017

Ju Hyun Kim

2

1 reference

26 November 2017

Tae-Hun Kim

3

1 reference

26 November 2017

Kwang Cheol Koh

4

1 reference

26 November 2017

Soon-Ho Um

5

1 reference

26 November 2017

Young Soo Kim

6

1 reference

26 November 2017

Kwan Sik Lee

7

1 reference

26 November 2017

Byung Hoon Han

8

1 reference

26 November 2017

Chae Yoon Chon

9

1 reference

26 November 2017

Joon-Yeol Han

10

1 reference

26 November 2017

Soo Hyung Ryu

11

1 reference

26 November 2017

Haak Cheoul Kim

12

1 reference

26 November 2017

Kwan Soo Byun

13

1 reference

26 November 2017

Seong Gyu Hwang

14

1 reference

26 November 2017

Byung-Ik Kim

15

1 reference

26 November 2017

Kwon Yoo

17

1 reference

26 November 2017

Heon-Ju Lee

18

1 reference

26 November 2017

Jae Seok Hwang

19

1 reference

26 November 2017

Yun Soo Kim

20

1 reference

26 November 2017

Young-Suk Lee

21

1 reference

26 November 2017

Sung-Kyu Choi

22

1 reference

26 November 2017

Youn-Jae Lee

23

1 reference

26 November 2017

Jin-Mo Yang

24

1 reference

26 November 2017

Joong-Won Park

25

1 reference

26 November 2017

Myung-Seok Lee

26

1 reference

26 November 2017

Dae-Ghon Kim

27

1 reference

26 November 2017

Young-Hwa Chung

28

1 reference

26 November 2017

Se-Hyun Cho

29

1 reference

26 November 2017

Jong-Young Choi

30

1 reference

26 November 2017

Young-Oh Kweon

31

1 reference

26 November 2017

Heon Young Lee

32

1 reference

26 November 2017

Hee-Won Yoo

34

1 reference

26 November 2017

Hyo-Suk Lee

35

1 reference

26 November 2017

language of work or name

English

0 references

publication date

1 October 2007

1 reference

26 November 2017

1 reference

26 November 2017

46

1 reference

26 November 2017

4

1 reference

26 November 2017

1041-1048

1 reference

Use of 2'-fluoro-5-methyl-beta-L-arabinofuranosyluracil as a novel antiviral agent for hepatitis B virus and Epstein-Barr virus

26 November 2017

1 reference

Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures

21 January 2018

1 reference

7 January 2021

Immunopathogenesis of hepatitis B e antigen negative chronic hepatitis B infection

1 reference

7 January 2021

Hepatitis B e antigen-negative chronic hepatitis B.

1 reference

7 January 2021

World-wide epidemiology of HBeAg-negative chronic hepatitis B and associated precore and core promoter variants

1 reference

7 January 2021

Hepatitis B e antigen-negative chronic hepatitis B in Hong Kong

1 reference

7 January 2021

Precore and core promoter mutations of hepatitis B virus and hepatitis B e antigen-negative chronic hepatitis B in Korea

1 reference

7 January 2021

Review article: current management of chronic hepatitis B.

1 reference

7 January 2021

Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study

1 reference

7 January 2021

Natural history of hepatitis B.

1 reference

7 January 2021

Management of chronic hepatitis B.

1 reference

7 January 2021

Extended lamivudine treatment in patients with HBeAg-negative chronic hepatitis B.

1 reference

7 January 2021

Course of virologic breakthroughs under long-term lamivudine in HBeAg-negative precore mutant HBV liver disease

1 reference

7 January 2021

Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine

1 reference

7 January 2021

Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update

1 reference

7 January 2021

A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update

1 reference

7 January 2021

1 reference

7 January 2021

Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B.

1 reference

7 January 2021

Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B.

1 reference

7 January 2021

Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B.

1 reference

7 January 2021

Entecavir resistance is rare in nucleoside naïve patients with hepatitis B

1 reference

7 January 2021

Inhibition of Epstein-Barr virus replication by a novel L-nucleoside, 2'-fluoro-5-methyl-beta-L-arabinofuranosyluracil

1 reference

7 January 2021

In vitro susceptibilities of wild-type or drug-resistant hepatitis B virus to (-)-beta-D-2,6-diaminopurine dioxolane and 2'-fluoro-5-methyl-beta-L-arabinofuranosyluracil

1 reference

7 January 2021

Inhibition of hepatitis B virus by a novel L-nucleoside, 2'-fluoro-5-methyl-beta-L-arabinofuranosyl uracil

1 reference

7 January 2021

Structure--activity relationships of 1-(2-Deoxy-2-fluoro-beta-L-arabinofuranosyl)pyrimidine nucleosides as anti-hepatitis B virus agents

1 reference

7 January 2021

Antiviral activity of clevudine [L-FMAU, (1-(2-fluoro-5-methyl-beta, L-arabinofuranosyl) uracil)] against woodchuck hepatitis virus replication and gene expression in chronically infected woodchucks (Marmota monax).

1 reference

7 January 2021

Kinetics of hepadnavirus loss from the liver during inhibition of viral DNA synthesis.

1 reference

7 January 2021

Residual integrated viral DNA after hepadnavirus clearance by nucleoside analog therapy

1 reference

7 January 2021

A phase II dose-escalating trial of clevudine in patients with chronic hepatitis B.

1 reference

7 January 2021

A 12-week clevudine therapy showed potent and durable antiviral activity in HBeAg-positive chronic hepatitis B.

1 reference

7 January 2021

Circulatory dysfunction in NAFLD--which is first, which is last, and what do we do in between?

1 reference

7 January 2021

Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B.

1 reference

7 January 2021

Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine

1 reference

7 January 2021

Identifiers

DOI

10.1002/HEP.21800

1 reference

26 November 2017

1 reference